News

All current employees at the Rochester manufacturing facility have become JHP employees. Peter Jenkins, CEO of JHP, said: “JHP is deeply appreciative of King’s support in the enormous

The companies say Xyzal is an oral antihistamine that has been shown to provide powerful allergy symptom relief. It is approved for use in adults and children six

The clinical trial was a multicenter, double-blind, placebo-controlled trial including 426 patients with major depression. According to the company, Lu AA21004 showed highly significant improvements on the primary

The approval of the supplemental biologics license application is based on prolonged overall survival from a large, randomized, multicenter, Phase III trial comparing Erbitux plus best supportive care

The drug, CVBT-141B, is formulated with human fibroblast growth factor-1 (FGF-1) and was applied topically in eight subjects at a single site. CardioVascular BioTherapeutics said that the formulation

This designation is based on a recommendation from the Committee for Orphan Medicinal Products. Dr Paul Laikind, president and CEO, said: “Patients with primary liver cancer often die

The decision means a delay to a milestone payment Vernalis is due from US partner Endo Pharmaceuticals. The $40 million payment triggered by an approval would have gone

In the study, patients with moderate to severe disease who achieved 75% improvement in psoriasis signs and symptoms at 12 weeks stopped receiving investigational anti-IL-12/23 antibody ABT-874. At

Emory University scientists found that the compound, known as gambogic amide, behaves much like nerve growth factor (NGF), a molecule found in the brain. NGF binds to TrkA,